AVERSION^® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. AVERSION^® Technology opioid analgesic product candidates are intended to provide effective relief from pain while discouraging common methods of pharmaceutical product misuse and abuse including:

• Intravenous injection by forming a viscous gelatinous mixture when tablets and capsules are dissolved in solvents suitable for injection; and More…



Drug abusers may dissolve currently marketed tablets or capsules containing abused drugs in water, alcohol, or other common solvents, filter the dissolved solution, and then inject the resulting fluid intravenously to obtain euphoric effects. In products and product candidates utilizing AVERSION^® Technology, extracting the active ingredient using generally available solvents, including water or alcohol, into a volume and form suitable for intravenous injection, converts the tablet into a viscous gel mixture and traps the active ingredient in the gel. Additionally, it is not possible, without difficulty, to draw this viscous gel through a needle into a syringe for I.V. injection. We believe that this gel-forming feature will limit or impede the ability of prospective I.V. drug abusers from extracting and injecting opioid active ingredients from products developed utilizing AVERSION^® Technology.

• Nasal snorting by inducing disliked nasal discomfort when tablets and capsules are crushed and snorted. More…



Drug abusers may crush or grind currently marketed pharmaceutical tablets or capsules and snort the resulting powder. The abused active ingredient in the powder is absorbed through the lining of the nasal passages providing the abuser with a rapid onset of euphoric effects. The combination of AVERSION^® Technology inactive ingredients is intended to induce nasal passage discomfort and disliking effects if the tablets are crushed and snorted. We believe products that utilize AVERSION^® Technology will discourage prospective nasal drug abusers from snorting crushed tablets.